We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

mRNA Assay Offers Applications in Clinical Biomarker Discovery

By LabMedica International staff writers
Posted on 27 Nov 2012
An mRNA quantitative assay is a simple, high-throughput, reproducible method, that offers a wide range of applications in clinical biomarker discovery and molecular testing to target personalized medicine.

The assay employs simple filtration of blood to capture leukocytes prior to extraction and purification of mRNA. This eliminates interference by the large amount of red blood cells in whole blood, and enables sensitive detection of changes in mRNA levels. The system adopts a 96-well microplate format, making it suitable for simultaneous processing of multiple samples. The drug response of an individual is simulated in a test tube by using whole blood samples stimulated with the drug. This system successfully brought a new "ex vivo" concept, which measures in vivo response in an in vitro assay and makes it possible to predict drug efficacy.

With this system, Hitachi Chemical (Tokyo, Japan) plans to conduct contract test services for pharmaceutical companies to find novel biomarkers and select subjects for clinical trials by predicting drug efficacy. It eventually aims to utilize the system as a companion diagnostic.

Related Links:
Hitachi Chemical


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test

Latest Clinical Chem. News

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders
27 Nov 2012  |   Clinical Chem.

Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis
27 Nov 2012  |   Clinical Chem.

Rapid D-Dimer Assay Supports Exclusion and Monitoring of Serious Clotting Conditions
27 Nov 2012  |   Clinical Chem.